JP2008520690A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008520690A5 JP2008520690A5 JP2007543228A JP2007543228A JP2008520690A5 JP 2008520690 A5 JP2008520690 A5 JP 2008520690A5 JP 2007543228 A JP2007543228 A JP 2007543228A JP 2007543228 A JP2007543228 A JP 2007543228A JP 2008520690 A5 JP2008520690 A5 JP 2008520690A5
- Authority
- JP
- Japan
- Prior art keywords
- group
- hydrogen
- alkyl
- hydroxy
- integer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229910052739 hydrogen Inorganic materials 0.000 claims 70
- 239000001257 hydrogen Substances 0.000 claims 70
- 125000000217 alkyl group Chemical group 0.000 claims 64
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 63
- 150000002431 hydrogen Chemical class 0.000 claims 56
- 125000003545 alkoxy group Chemical group 0.000 claims 16
- YZCKVEUIGOORGS-OUBTZVSYSA-N deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 claims 16
- 229910052805 deuterium Inorganic materials 0.000 claims 16
- 125000001153 fluoro group Chemical group F* 0.000 claims 16
- 125000003709 fluoroalkyl group Chemical group 0.000 claims 16
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims 16
- 125000004043 oxo group Chemical group O=* 0.000 claims 16
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 16
- UFHFLCQGNIYNRP-UHFFFAOYSA-N hydrogen Chemical group [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 14
- 239000008194 pharmaceutical composition Substances 0.000 claims 13
- 125000006239 protecting group Chemical group 0.000 claims 9
- 125000001118 alkylidene group Chemical group 0.000 claims 8
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 8
- 229910052757 nitrogen Inorganic materials 0.000 claims 8
- 125000004433 nitrogen atoms Chemical group N* 0.000 claims 8
- 125000004430 oxygen atoms Chemical group O* 0.000 claims 8
- 229910052717 sulfur Inorganic materials 0.000 claims 8
- 125000004434 sulfur atoms Chemical group 0.000 claims 8
- 150000001875 compounds Chemical class 0.000 claims 7
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 claims 7
- 239000011710 vitamin D Substances 0.000 claims 6
- 229940046008 Vitamin D Drugs 0.000 claims 4
- 229930003316 Vitamin D Natural products 0.000 claims 4
- 235000019166 vitamin D Nutrition 0.000 claims 4
- 150000003710 vitamin D derivatives Chemical class 0.000 claims 4
- 210000003491 Skin Anatomy 0.000 claims 3
- 241001465754 Metazoa Species 0.000 claims 2
- 206010052779 Transplant rejections Diseases 0.000 claims 2
- 229940119350 dehydroepiandrosterone Drugs 0.000 claims 2
- 230000002401 inhibitory effect Effects 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 229960002847 prasterone Drugs 0.000 claims 2
- 210000000577 Adipose Tissue Anatomy 0.000 claims 1
- 208000006673 Asthma Diseases 0.000 claims 1
- 206010003816 Autoimmune disease Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 206010012601 Diabetes mellitus Diseases 0.000 claims 1
- 206010021972 Inflammatory bowel disease Diseases 0.000 claims 1
- 206010024324 Leukaemias Diseases 0.000 claims 1
- 206010025135 Lupus erythematosus Diseases 0.000 claims 1
- 210000000138 Mast Cells Anatomy 0.000 claims 1
- 208000008589 Obesity Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 206010039073 Rheumatoid arthritis Diseases 0.000 claims 1
- 210000002374 Sebum Anatomy 0.000 claims 1
- 229940088594 Vitamin Drugs 0.000 claims 1
- AEDMQUAPBVOJNN-UHFFFAOYSA-N [3-[2-[4-[2-(trifluoromethyl)phenoxy]piperidin-1-yl]-1,3-thiazol-5-yl]-1,2,4-oxadiazol-5-yl]methanol Chemical compound O1C(CO)=NC(C=2SC(=NC=2)N2CCC(CC2)OC=2C(=CC=CC=2)C(F)(F)F)=N1 AEDMQUAPBVOJNN-UHFFFAOYSA-N 0.000 claims 1
- 201000009596 autoimmune hypersensitivity disease Diseases 0.000 claims 1
- 230000024245 cell differentiation Effects 0.000 claims 1
- -1 dehydroepiandrosterone vitamin D Chemical class 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 230000036571 hydration Effects 0.000 claims 1
- 238000006703 hydration reaction Methods 0.000 claims 1
- 200000000018 inflammatory disease Diseases 0.000 claims 1
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 235000020824 obesity Nutrition 0.000 claims 1
- 210000000056 organs Anatomy 0.000 claims 1
- 238000007911 parenteral administration Methods 0.000 claims 1
- 239000000546 pharmaceutic aid Substances 0.000 claims 1
- 201000004681 psoriasis Diseases 0.000 claims 1
- 201000006409 renal osteodystrophy Diseases 0.000 claims 1
- 230000028327 secretion Effects 0.000 claims 1
- 201000000849 skin cancer Diseases 0.000 claims 1
- ILMRJRBKQSSXGY-UHFFFAOYSA-N tert-butyl(dimethyl)silicon Chemical group C[Si](C)C(C)(C)C ILMRJRBKQSSXGY-UHFFFAOYSA-N 0.000 claims 1
- 230000000699 topical Effects 0.000 claims 1
- 230000035897 transcription Effects 0.000 claims 1
- 239000011782 vitamin Substances 0.000 claims 1
- 235000013343 vitamin Nutrition 0.000 claims 1
- 229930003231 vitamins Natural products 0.000 claims 1
- 230000037303 wrinkles Effects 0.000 claims 1
Claims (20)
を有する化合物。 The following formula:
A compound having
を有する化合物。 The following formula:
A compound having
を有する17(20)−デヒドロビタミンD類似体の有効量を含む、乾癬を治療するための医薬組成物。 The following formula:
A pharmaceutical composition for treating psoriasis comprising an effective amount of a 17 (20) -dehydrovitamin D analog having:
またはqが2から5の整数である−(CH2)q−基を表し、そしてここでR5は水素、ヒドロキシ、保護されたヒドロキシ、またはC1−5アルキルを表し、そしてここで側鎖の20位、22位、もしくは23位のCH−基のいずれかは窒素原子で置き換えられてよい、またはここで20位、22位、および23位の−CH(CH3)−基、− (CH2)m−基、CR1R2−基もしくは− (CH2)n−基のいずれかは各々、酸素原子もしくはイオウ原子で置き換えられてよい]
を有する17(20)−デヒドロビタミンD類似体の有効量を含む、白血病、大腸癌、乳癌、皮膚癌または前立腺癌から成る群より選択される疾患の治療のための医薬組成物。 The following formula:
Or a — (CH 2 ) q — group where q is an integer from 2 to 5, and R 5 represents hydrogen, hydroxy, protected hydroxy, or C 1-5 alkyl, and wherein the side chain Any one of the CH-groups at the 20-position, 22-position, or 23-position may be replaced by a nitrogen atom, or a -CH (CH 3 )-group at the 20-position, 22-position, and 23-position,-( Any of the CH 2 ) m — group, CR 1 R 2 — group or — (CH 2 ) n — group may each be replaced by an oxygen atom or a sulfur atom]
A pharmaceutical composition for the treatment of a disease selected from the group consisting of leukemia, colon cancer, breast cancer, skin cancer or prostate cancer, comprising an effective amount of 17 (20) -dehydrovitamin D analog having:
を有する17(20)−デヒドロビタミンD類似体の有効量を含む、多発性硬化症、ループス、糖尿病、宿主対移植片の拒絶、および臓器移植の拒絶から成る群より選択される自己免疫疾患の治療のための医薬組成物。 The following formula:
An autoimmune disease selected from the group consisting of multiple sclerosis, lupus, diabetes, host versus graft rejection, and organ transplant rejection, comprising an effective amount of a 17 (20) -dehydrovitamin D analog having A pharmaceutical composition for treatment .
を有する17(20)−デヒドロビタミンD類似体の有効量を含む、関節リウマチ、喘息、および炎症性腸疾患から成る群より選択される炎症性疾患の治療のための医薬組成物。 The following formula:
A pharmaceutical composition for the treatment of an inflammatory disease selected from the group consisting of rheumatoid arthritis, asthma, and inflammatory bowel disease, comprising an effective amount of 17 (20) -dehydrovitamin D analog having:
を有する17(20)−デヒドロビタミンD類似体の有効量を含む、しわ、適度の皮膚の固さの欠如、適度の皮膚の水和作用の欠如、および不十分な皮脂の分泌から成る群より選択される皮膚の状態の治療のための医薬組成物。 The following formula:
17 (20) having - an effective amount of dehydroepiandrosterone vitamin D analog, wrinkles, lack of firmness moderate skin, lack of hydration of moderate skin and more poor group consisting sebum secretion A pharmaceutical composition for the treatment of selected skin conditions.
を有する17(20)−デヒドロビタミンD類似体の有効量を含む、腎性骨異栄養症の治療のための医薬組成物。 The following formula:
17 (20) having - dehydroepiandrosterone vitamin containing an effective amount of D analogs, a pharmaceutical composition for the treatment of renal osteodystrophy.
を有する17(20)−デヒドロビタミンD類似体の有効量を含む、動物の肥満を治療もしくは予防する、動物における肥満細胞の分化を阻害する、SCD−1遺伝子の転写を阻害する、および/または体脂肪を低減するための医薬組成物。 The following formula:
Treating or preventing obesity in animals, inhibiting mast cell differentiation in animals, inhibiting transcription of the SCD-1 gene, and / or comprising an effective amount of a 17 (20) -dehydrovitamin D analog having A pharmaceutical composition for reducing body fat.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US63000704P | 2004-11-22 | 2004-11-22 | |
US60/630,007 | 2004-11-22 | ||
PCT/US2005/041670 WO2006057885A2 (en) | 2004-11-22 | 2005-11-18 | 17,20(e)-dehydro vitamin d analogs and their uses |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2008520690A JP2008520690A (en) | 2008-06-19 |
JP2008520690A5 true JP2008520690A5 (en) | 2009-01-15 |
JP5043673B2 JP5043673B2 (en) | 2012-10-10 |
Family
ID=36216285
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2007543228A Expired - Fee Related JP5043673B2 (en) | 2004-11-22 | 2005-11-18 | 17,20 (E) -dehydrovitamin D analogues and their use |
JP2007543269A Pending JP2008520705A (en) | 2004-11-22 | 2005-11-18 | 2-Methylene-19-nor-1α-hydroxy-17-ene-homopregnacalciferol and uses thereof |
JP2007543268A Expired - Fee Related JP5161582B2 (en) | 2004-11-22 | 2005-11-18 | 17,20 (Z) -dehydrovitamin D analogues and their use |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2007543269A Pending JP2008520705A (en) | 2004-11-22 | 2005-11-18 | 2-Methylene-19-nor-1α-hydroxy-17-ene-homopregnacalciferol and uses thereof |
JP2007543268A Expired - Fee Related JP5161582B2 (en) | 2004-11-22 | 2005-11-18 | 17,20 (Z) -dehydrovitamin D analogues and their use |
Country Status (11)
Country | Link |
---|---|
US (6) | US7241750B2 (en) |
EP (3) | EP1817279B1 (en) |
JP (3) | JP5043673B2 (en) |
AT (3) | ATE469127T1 (en) |
AU (3) | AU2005309790B2 (en) |
CA (3) | CA2588401C (en) |
DE (3) | DE602005020842D1 (en) |
ES (3) | ES2347058T3 (en) |
MX (3) | MX2007006546A (en) |
NZ (3) | NZ555282A (en) |
WO (3) | WO2006057901A2 (en) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030188756A1 (en) * | 2002-08-19 | 2003-10-09 | Cantorna Margherita T | Treatment of inflammatory bowel disease with vitamin d compounds |
US8404667B2 (en) | 2006-12-29 | 2013-03-26 | Wisconsin Alumni Research Foundation | Compounds, compositions, kits and methods of use to orally and topically treat acne and other skin conditions by 19-Nor vitamin D analog |
CA2588401C (en) | 2004-11-22 | 2013-02-12 | Wisconsin Alumni Research Foundation | 17,20(z)-dehydro vitamin d analogs and their uses |
DE602005021245D1 (en) * | 2004-11-22 | 2010-06-24 | Wisconsin Alumni Res Found | 2-METHYLENE-19,26,27-TRINOR- (20S) -1-ALPHA-HYDROXYVITAMINE D3 AND ITS USES |
CA2676512A1 (en) * | 2007-01-25 | 2008-07-31 | Bioxell S.P.A. | Synthesis of 1.alpha.-fluoro-25-hydroxy-16-23e-diene-26,27-bishomo-20-epi-cholecalciferol |
US7888339B2 (en) * | 2008-07-10 | 2011-02-15 | Wisconsin Alumni Research Foundation | 2-methylene-20(21)-dehydro-19-nor-vitamin D analogs |
US7893043B2 (en) * | 2008-07-10 | 2011-02-22 | Wisconsin Alumni Research Foundation | 2-methylene-(17Z)-17(20)-dehydro-19,21-dinor-vitamin D analogs |
AU2009337184A1 (en) * | 2009-01-16 | 2011-07-28 | Anzamed International Limited | Medicament for the treatment of pain and inflammation |
WO2011011706A2 (en) * | 2009-07-24 | 2011-01-27 | The Johns Hopkins University | Methods and compositions for treating or preventing autoimmune diseases using immunomodulatory agents |
MX2012003883A (en) * | 2009-10-02 | 2012-06-27 | Wisconsin Alumni Res Found | (20s,22e)-2-methylene-19-nor-22-ene-1î±,25-dihydroxyvitamin d3 analogs. |
WO2011119610A2 (en) * | 2010-03-23 | 2011-09-29 | Wisconsin Alumni Research Foundation | (20S)-2-METHYLENE-19-NOR-22-DIMETHYL-1α,25- DIHYDROXYVITAMIN D3 AND (20R)-2-METHYLENE-19-NOR-22- DIMETHYL-1α,25-HYDROXYVITAMIN D3 |
US8664206B2 (en) | 2010-03-23 | 2014-03-04 | Wisconsin Alumni Research Foundation | Diastereomers of 2-methylene-19-nor-22-methyl-1α,25-dihydroxyvitamin D3 |
AU2011232562B2 (en) * | 2010-03-23 | 2014-10-02 | Wisconsin Alumni Research Foundation | Diastereomers of 2-methylene-19-nor-22-methyl-1alpha,25- dihydroxyvitamin D3 |
JP6114292B2 (en) * | 2011-10-21 | 2017-04-12 | ウイスコンシン アラムニ リサーチ ファンデーション | 2-Methylene-vitamin D analogs and their use |
Family Cites Families (37)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4666634A (en) * | 1984-12-05 | 1987-05-19 | Chugai Seiyaku Kabushiki Kaisha | vitamin D3 derivatives having a substituent at 2-position |
US5145846A (en) * | 1988-01-20 | 1992-09-08 | Hoffmann-La Roche Inc. | Vitamin D3 analogs |
US5362719A (en) * | 1990-03-01 | 1994-11-08 | Leo Pharmaceutical Products, Ltd. A/S Lovens Kemiske Fabrik Produktionsaktieselskab) | Use of vitamin-D analogues in the treatment of acne |
GB9004544D0 (en) * | 1990-03-01 | 1990-04-25 | Leo Pharm Prod Ltd | Novel treatment ii |
ATE116859T1 (en) * | 1990-07-04 | 1995-01-15 | Marcin Krotkiewski | BLOOD PRESSURE-LOWERING PREPARATION. |
US5086191A (en) * | 1991-05-28 | 1992-02-04 | Wisconsin Alumni Research Foundation | Intermediates for the synthesis of 19-nor vitamin D compounds |
GB9214202D0 (en) * | 1992-07-03 | 1992-08-12 | Leo Pharm Prod Ltd | Chemical compounds |
DE69400495T2 (en) * | 1993-04-05 | 1997-04-30 | Wisconsin Alumni Res Found | 19-nor-vitamin D3 compound with a substituent in the 2nd position |
US5552392A (en) * | 1993-11-03 | 1996-09-03 | Wisconsin Alumni Research Foundation | Method of treating hypoparathyroidism with (20S) vitamin D compounds |
DK0717034T3 (en) * | 1994-12-14 | 1999-10-18 | Duphar Int Res | Vitamin D compounds and methods for preparing these compounds |
GB9625271D0 (en) * | 1996-12-04 | 1997-01-22 | Leo Pharm Prod Ltd | Chemical compounds |
PL336231A1 (en) * | 1997-02-13 | 2000-06-19 | Bone Care International | System for aimed therapeutic delivery of vitamin d compounds |
US5843928A (en) * | 1997-03-17 | 1998-12-01 | Wisconsin Alumni Research Foundation | 2-alkylidene-19-nor-vitamin D compounds |
US5945410A (en) * | 1997-03-17 | 1999-08-31 | Wisconsin Alumni Research Foundation | 2-alkyl-19-nor-vitamin D compounds |
US6316642B1 (en) * | 1997-03-17 | 2001-11-13 | Wisconsin Alumni Research Foundation | 26,27-Homologated-20-EPI-2alkyl-19-nor-vitamin D compounds |
US6392071B1 (en) * | 1997-03-17 | 2002-05-21 | Wisconsin Alumni: Research Foundation | 26,27-homologated-20-EPI-2-alkylidene-19-nor-vitamin D compounds |
US6306844B1 (en) * | 1997-03-17 | 2001-10-23 | Wisconsin Alumni Research Foundation | Use of 2α-methyl-19-nor-20(S)-1α, 25-dihydroxyvitamin D3 to increase bone strength |
US5936105A (en) * | 1997-06-13 | 1999-08-10 | Tetrionics, Inc. | 14-EPI-19-nor-vitamin D compounds and methods |
KR100593238B1 (en) * | 1997-06-25 | 2006-06-26 | 데이진 가부시키가이샤 | Vitamin D3 derivatives and remedies for inflammatory respiratory diseases prepared from the same |
GB9721156D0 (en) * | 1997-10-06 | 1997-12-03 | Leo Pharm Prod Ltd | Novel vitamin d analogues |
ATE515265T1 (en) * | 1998-03-27 | 2011-07-15 | Univ Oregon Health & Science | VITAMIN D AND ITS ANALOGUES FOR THE TREATMENT OF TUMORS AND OTHER HYPERPROLIFERATIVE DISEASES |
DK1286962T3 (en) * | 2000-05-31 | 2008-10-06 | Wisconsin Alumni Res Found | 2-Ethyl and 2-ethylidene-19-nor-vitamin D compounds |
EP2070911A2 (en) * | 2000-07-18 | 2009-06-17 | Bone Care International, Inc. | Stabilized 1Alpha-Hydroxy vitamin D |
US6440953B1 (en) * | 2000-09-08 | 2002-08-27 | Wisconsin Alumni Research Foundation | 1α-hydroxy-2-methylene-19-nor-homopregnacalciferol and its uses |
EP1392323B1 (en) | 2001-05-22 | 2008-10-08 | Bioxell S.p.a. | Use of a vitamin d3 analogue for the treatment of autoimmune diabetes |
US6627622B2 (en) * | 2002-02-18 | 2003-09-30 | Wisconsin Alumni Research Foundation | (20S)-1α-hydroxy-2-methylene-19-nor-bishomopregnacalciferol and its uses |
US6566352B1 (en) * | 2002-02-18 | 2003-05-20 | Wisconsin Alumni Research Foudation | 1 α-hydroxy-2-methylene-19-nor-pregnacalciferol and its uses |
MXPA04008227A (en) * | 2002-03-29 | 2005-08-19 | Wisconsin Alumni Res Found | METHOD OF SYNTHESIZING 1alpha-HYDROXY-2-METHYLENE-19-NOR-HOMOPREGNACALCIFEROL. |
US6846811B2 (en) * | 2002-04-22 | 2005-01-25 | Wisconsin Alumni Research Foundation | (20S) 1α-hydroxy-2α-methyl and 2β-methyl-19-nor-vitamin D3 and their uses |
GB0305332D0 (en) | 2003-03-10 | 2003-04-09 | Leuven K U Res & Dev | Biological evaluation of novel vitamin D analogues |
US20050009792A1 (en) | 2003-07-08 | 2005-01-13 | Deluca Hector F. | (20S)-1alpha-hydroxy-2-methylene-19-nor-vitamin D3 and its uses |
JP2007512376A (en) * | 2003-11-25 | 2007-05-17 | ウイスコンシン アラムニ リサーチ ファンデーション | Vitamin D analogs for the prevention and treatment of obesity |
US7053075B2 (en) * | 2003-11-25 | 2006-05-30 | Deluca Hector F | Methods for reducing body fat using vitamin D compounds |
CA2588401C (en) * | 2004-11-22 | 2013-02-12 | Wisconsin Alumni Research Foundation | 17,20(z)-dehydro vitamin d analogs and their uses |
WO2006057884A2 (en) | 2004-11-22 | 2006-06-01 | Wisconsin Alumni Research Foundation | 2α-METHYL AND 2ß-METHYL ANALOGS OF 19,26,27-TRINOR-(20S)-1α-HYDROXYVITAMIN D3 AND THEIR USES |
JP2009532458A (en) | 2006-04-06 | 2009-09-10 | ウイスコンシン アラムニ リサーチ ファンデーション | 2-Methylene-1α-hydroxy-19,21-dinorvitamin D3 analog and use thereof |
CA2683628C (en) * | 2007-04-25 | 2018-03-06 | Cytochroma Inc. | Method of treating vitamin d insufficiency and deficiency |
-
2005
- 2005-11-18 CA CA2588401A patent/CA2588401C/en not_active Expired - Fee Related
- 2005-11-18 NZ NZ555282A patent/NZ555282A/en not_active IP Right Cessation
- 2005-11-18 WO PCT/US2005/041820 patent/WO2006057901A2/en active Application Filing
- 2005-11-18 JP JP2007543228A patent/JP5043673B2/en not_active Expired - Fee Related
- 2005-11-18 AT AT05849730T patent/ATE469127T1/en not_active IP Right Cessation
- 2005-11-18 WO PCT/US2005/041819 patent/WO2006057900A2/en active Application Filing
- 2005-11-18 DE DE602005020842T patent/DE602005020842D1/en active Active
- 2005-11-18 AU AU2005309790A patent/AU2005309790B2/en not_active Ceased
- 2005-11-18 MX MX2007006546A patent/MX2007006546A/en active IP Right Grant
- 2005-11-18 MX MX2007006261A patent/MX2007006261A/en active IP Right Grant
- 2005-11-18 EP EP05849730A patent/EP1817279B1/en not_active Not-in-force
- 2005-11-18 AT AT05851805T patent/ATE469883T1/en not_active IP Right Cessation
- 2005-11-18 NZ NZ555278A patent/NZ555278A/en not_active IP Right Cessation
- 2005-11-18 MX MX2007006262A patent/MX2007006262A/en active IP Right Grant
- 2005-11-18 CA CA2588396A patent/CA2588396C/en not_active Expired - Fee Related
- 2005-11-18 EP EP05851757A patent/EP1828114B1/en not_active Not-in-force
- 2005-11-18 JP JP2007543269A patent/JP2008520705A/en active Pending
- 2005-11-18 AT AT05851757T patent/ATE465144T1/en not_active IP Right Cessation
- 2005-11-18 AU AU2005309805A patent/AU2005309805B2/en not_active Ceased
- 2005-11-18 ES ES05851805T patent/ES2347058T3/en active Active
- 2005-11-18 WO PCT/US2005/041670 patent/WO2006057885A2/en active Application Filing
- 2005-11-18 JP JP2007543268A patent/JP5161582B2/en not_active Expired - Fee Related
- 2005-11-18 ES ES05851757T patent/ES2344989T3/en active Active
- 2005-11-18 AU AU2005309806A patent/AU2005309806B2/en not_active Expired - Fee Related
- 2005-11-18 CA CA2588410A patent/CA2588410C/en not_active Expired - Fee Related
- 2005-11-18 NZ NZ555277A patent/NZ555277A/en not_active IP Right Cessation
- 2005-11-18 US US11/283,125 patent/US7241750B2/en active Active
- 2005-11-18 DE DE602005021538T patent/DE602005021538D1/en active Active
- 2005-11-18 US US11/283,291 patent/US7241752B2/en active Active
- 2005-11-18 US US11/283,090 patent/US7241748B2/en active Active
- 2005-11-18 EP EP05851805A patent/EP1846370B1/en not_active Not-in-force
- 2005-11-18 DE DE602005021702T patent/DE602005021702D1/en active Active
- 2005-11-18 ES ES05849730T patent/ES2346774T3/en active Active
-
2007
- 2007-07-09 US US11/775,061 patent/US8232263B2/en not_active Expired - Fee Related
- 2007-07-09 US US11/775,117 patent/US7704982B2/en not_active Expired - Fee Related
- 2007-07-09 US US11/775,108 patent/US7741313B2/en not_active Expired - Fee Related
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2008520690A5 (en) | ||
JP2008520704A5 (en) | ||
JP2008520703A5 (en) | ||
JP2008520705A5 (en) | ||
CA2597624A1 (en) | 2-methylene-19-nor-(20s-24s)-1.alpha.,25-dihydroxyvitamin-d2 | |
JP2008520691A5 (en) | ||
JP2009525981A5 (en) | ||
JP2010505739A5 (en) | ||
JP2007532540A5 (en) | ||
EP2979700B1 (en) | Antitumor agent including low dose irinotecan hydrochloride hydrate | |
CN101829108A (en) | Application of diterpene ginkgolide | |
JP2006500388A5 (en) | ||
JP2002533335A5 (en) | ||
JP2008520716A5 (en) | ||
TW202114691A (en) | Method for treating malignant tumor | |
JP2006523239A5 (en) | ||
CA2516233A1 (en) | 2-propylidene-19-nor-vitamin d compounds | |
JP2008530109A5 (en) | ||
JP4630914B2 (en) | Liver fibrosis inhibitor | |
JP2011527695A5 (en) | ||
JP2008545803A5 (en) | ||
JP2010513489A5 (en) | ||
RU2012138162A (en) | Pyridazine derivatives for use as cannabinod-2 agonists | |
JP2011527699A5 (en) | ||
JP2005527558A5 (en) |